The global market is expected to enjoy a valuation of USD 123.2 Billion by the end of the year 2023, and further expand at a CAGR of 5.2% to reach a valuation of ~USD 205.3 Billion by the year 2033.According to the recent study by Future Market Insights, degenerative diseases are leading the market with an expected share of about 31.7% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 117.6 Billion |
| Market Value 2023 | USD 123.2 Billion |
| Market Value 2033 | USD 205.3 Billion |
| CAGR 2023 to 2033 | 5.2% |
| Market Share of Top 5 Countries (2022) | 54.8% |
| Key Market Players List | Abbvie Inc; Alkermes Plc; Allergan Plc; AstraZeneca Plc; BIAL Group; Bristol-myers Squibb; Eisai Co, Ltd.; Endo Pharmaceuticals; Eli Lilly and Co; and F. Hoffmann-La Roche Ltd. |
The CNS or central nervous system is the coordinating or control mechanism of the animal body, including humans. Degeneration of nervous tissues or disorders in the brain and spinal cords is the prominent reason for several types of neurodegenerative diseases.
New research activities conducted in the sphere of mental health and psychiatric disorders have increased the demand for treatment and therapeutic opportunities available in the CNS treatment and therapy market.
The growth of CNS therapeutics for the soaring cases of mental illness and central nervous system disorders associated with faulty lifestyle is providing the necessary impetus for the establishment and growth of the CNS treatment and therapy market across the geographical regions.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The market value for CNS treatment and therapy was around 57.8% of the overall ~USD 203.6 Billion of the global antibody therapy market in 2022.
The sale of CNS treatment and therapy expanded at a CAGR of 4.66% from 2017 to 2022.
Over the years, increased incidents of psychological disorders and nervous breakdown have emerged as a major concern across the globe. By the applications of several types of chemical formulations such as anaesthetic anti-Parkinson's drugs and antiepileptic drugs, the CNS treatment and therapy has relieved many patients across the globe, creating a huge market.
According to Parkinson's Foundation, the global count of patients suffering from Parkinson's disease is estimated to be 10 million in 2022. The diagnosis report for other nervous system disorder diseases have also increased significantly in the recent past and is estimated to reach 82 million by 2030. This situation creates ample of opportunity for pharmaceutical companies to generate revenues by delivering treatment and therapeutic options for the patients.
Increased government funding to accelerate the clinical development of newly discovered drugs is expected to fuel the rapid growth of the central nervous system therapeutics market during the forecast period. The introduction of new therapies like serotonin and norepinephrine reuptake inhibitors (SNRIs) have acquired huge traction within a short period of time.
Thus, owing to the aforementioned factors, the global CNS treatment and therapy market is projected to expand at a CAGR of 5.2% during the forecast period between 2023 and 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan-Jun (H1), 2021 (A) | 3.99% |
| Jul-Dec (H2), 2021 (A) | 5.13% |
| Jan-Jun (H1),2022 Projected (P) | 3.70% |
| Jan-Jun (H1),2022 Outlook (O) | 4.00% |
| Jul-Dec (H2), 2022 Outlook (O) | 5.26% |
| Jul-Dec (H2), 2022 Projected (P) | 5.03% |
| Jan-Jun (H1), 2023 Projected (P) | 3.87% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 30↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 1↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 22↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 12↑ |
According to the Alzheimer’s Association, the number of patients suffering from Alzheimer’s is predicted to reach nearly 13 billion in the USA alone by 2050. Alzheimer’s, along with other neurological disorders in the ageing population, is predicted to keep demand for CNS treatment and therapy services high in the USA market and other regions as well.
New product launches by adopting upgraded techniques are the prospective growth strategy that is adopted by major market players operating in the central nervous system therapeutics market. For instance, the Corbus Pharmaceutical Inc. of Japan started the commercialization of the Lenabasum drug in Japan by entering into an agreement with Kaken pharmaceutical company in 2019.
The rising cases of mental health disorders among the general population has provided the necessary impetus for the central and regional governments to make necessary provisions for the treatment of CNS disorders. Canada released its first national strategy for controlling dementia by spending USD 200 Million though the Canadian Institute of Health Research in 2019.
The global CNS therapeutics is categorized based on the class of drugs used for the treatment of central nervous system disorders. Immunomodulators and interferon are analysed to be constantly driving the central nervous treatment drug market by the innovation of therapeutic molecules implemented for the treatment of neurological diseases symptoms.
Strong guidelines for the approval of newly developed drug Formulations before introduction into the market hamper the competitive edge of pharmaceutical companies investing heavily in research and development. Failure rates of various newly introduced drugs for nervous system therapeutics is also higher, which poses a major challenge for the growth of the market.
The wide availability of generic drugs is also anticipated to limit the growth of private market players supplying neurological disorder drugs, anaesthetics, anti-Parkinson drugs and its other variants. Agreement with government organizations to supply neurological disease prevention products can be established to incur higher profit from the CNS treatment and therapy services.
The introduction of novel drug delivery systems in the past decade have faced the issue of its acceptance in healthcare sectors of all regions.
Dissemination of proper information to the CNS treatment and therapy centres is the underlying challenge that may hinder the market players from realizing their full potential.
| Country | USA |
|---|---|
| 2023 | 31.70% |
| 2033 | 31.20% |
| BPS Analysis | -52 |
| Country | Germany |
|---|---|
| 2023 | 6.70% |
| 2033 | 7.20% |
| BPS Analysis | 46 |
| Country | UK |
|---|---|
| 2023 | 5.70% |
| 2033 | 5.70% |
| BPS Analysis | -3 |
| Country | Canada |
|---|---|
| 2023 | 5.70% |
| 2033 | 5.70% |
| BPS Analysis | 7 |
| Country | China |
|---|---|
| 2023 | 5.60% |
| 2033 | 6.20% |
| BPS Analysis | 59 |
The USA is set to hold a total market share of about 31.7% in 2023.
The primary causes of these enormous market growth tendencies in the USA market includes rising percentage of the elderly population and the greatest level of healthcare spending. The demand within the global market is projected to rise as people become more aware of the neurodegenerative illnesses, autoimmune and inflammatory disorders, and their potential for treatment.
Germany is set to hold a market share of nearly 6.7% in the global CNS treatment and therapy market in 2023.
Given the intricacy of the condition and the scarcity of accessible controlled research, among the most sensitive issues in neuro-oncology is the treatment of primary CNS lymphoma. The European Association of Neuro-Oncology established a multidisciplinary task force in 2013 to develop evidence-based recommendations for immunocompetent adults with primary CNS lymphoma.
The recommendations cover topics such as the management of aged patients as well as features of care for surgery, systemic and intrathecal chemotherapy, intense chemotherapy with autologous stem-cell transplantation, radiation, and ophthalmic symptoms. The recommendations should support doctors in their day-to-day work and decision-making, act as a foundation for next neuro-oncology studies, and increase market value in Germany.
China contributes about 5.6% revenue share to the global market.
China has become a significant market for anesthetics anti-Parkinson medications as a result of modernizing its healthcare infrastructure. With the increasing development and manufacturing of novel biologics for CNS treatment, the market is set to advance, as Chinese manufacturing firms take more outsourcing activities.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Biologics are set to hold a share of around 68.7% in the global market, in 2023.
The blood brain barrier (BBB), which hinders attaining enough drug concentrations at sites of action, precludes many central nervous system (CNS) illnesses from being properly treated by systemically delivered medicines. Direct CNS delivery will probably play a bigger part in therapy as a result of the rising prevalence of neurodegenerative illnesses and the inability of most systemically delivered medicines to penetrate the blood-brain barrier.
This problem is solved by administering big chemicals, cells, viral vectors, oligonucleotides, and other innovative therapeutics directly to the CNS through the subarachnoid space, ventricular system, or parenchyma.
Antidepressant segment holds about one-third value share within the global market.
CNS depressants are prescribed to treat seizures, anxiety, panic attacks, and sleeplessness. They can also be administered before surgery to calm nerves and relax. Sedatives, tranquillizers, and hypnotics are medications that depress the central nervous system (CNS). These medications can reduce brain activity, making them effective for treating anxiety, panic attacks, severe stress reactions, and sleep difficulties.
Degenerative diseases are set to hold a share of around 31.7% in the global market, in 2023.
Millions of people worldwide are affected by neurodegenerative disorders. The two most prevalent neurodegenerative illnesses are Alzheimer's disease and Parkinson's disease. According to an estimate from the Alzheimer's Disease Association, 6.2 million people in the USA had Alzheimer's disease by 2022.
Hospital pharmacies segment is set to hold a share of around 48.6% in the global market, in 2023.
Increasing prevalence of neurodegenerative disorders, as well as the rising patient inflow into hospital settings are factors propelling institutional sales within the hospital pharmacies. With appropriate prescription and treatment regime, this segment is set to expand over the forecast period, owed to greater patient compliance, as well as availability of medications in-house.
The various regional players operating in CNS therapeutics market adopt acquiring government funding to support novel research activities in the field of nervous system disorder diseases.
Global players with higher valuation incur higher spending on clinical trials of different products such as anesthetic anti-Parkinson drugs for launching it in market. Strategic collaborations is the major strategy adopted by such market players to expand their consumer base.
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the CNS treatment and therapy space, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Drug, Drug Class, Disease, Distribution Channel, and Region |
| Key Companies Profiled | AbbVie Inc,; Alkermes Plc,; Allergan Plc,; AstraZeneca Plc,; BIAL Group,; Bristol-myers Squibb,; Eisai Co, Ltd.,; Endo Pharmaceuticals,; Eli Lilly and Co,; F. Hoffmann-La Roche Ltd. |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The market is estimated to acquire USD 123.2 billion in 2023.
Nonselective, multipotent therapies appear to be more effective, thus propelling market growth.
The United States accounts for 31% of the market in 2023.
Germany holds a market share of nearly 6.7% in the market in 2023.
The scarcity of accessible controlled research, among the most sensitive issues is driving growth.
| Market Size (2023) | USD 235.0 billion |
|---|---|
| Market Size (2033) | USD 824.0 billion |
| Market CAGR (2023 to 2033) | 13.4% |
| Expected Market Value (2023) | USD 10 Million |
|---|---|
| Anticipated Forecast Value (2033) | USD 17.91 Million |
| Projected CAGR (2023 to 2033) | 6% |
| Estimated Base Year Value (2021) | USD 1.1 Billion |
|---|---|
| Expected Market Value (2026) | USD 1.7 Billion |
| Projected Growth Rate (2022 to 2032) | 6.1% |
Explore Therapy Area Insights
View Reports
CNS Treatment and Therapy Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
